Efgartigimod PH20 SC clinical trials
8 indexed studies · 4 currently recruiting
- RecruitingPHASE2
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
This study is testing a new medicine, efgartigimod, for adults with systemic sclerosis. It aims to see if the medicine helps improve symptoms and if it's safe, compared to a dummy medicine. We're looking for people to join for about 15 months.
For: Systemic Sclerosis (SSc)United States · Argentina · Belgium - Enrolling by invitationPHASE3
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
This study looks at a new medicine called efgartigimod for people with certain muscle conditions like myositis. It's for adults who were in a previous study, to see if the medicine is safe and helpful over a long time.
For: Myositis · Active Idiopathic Inflammatory Myopathy · DermatomyositisUnited States · Argentina · Austria - Active not recruitingPHASE2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
This study looks at a new drug, efgartigimod, for adults with CIDP, a nerve condition. It aims to see how safe and effective it is over a long time when given under the skin. Some participants might also try taking the drug less often.
For: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)United States · Austria · Belgium - Active not recruitingPHASE3
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
This study looks at a new medicine for adults with a type of muscle weakness affecting the eyes called ocular myasthenia gravis. Researchers want to see if the medicine, Efgartigimod, is safe and helps improve eye symptoms. Some people will get the active medicine, and others will get a dummy treatment.
For: Myasthenia Gravis, OcularUnited States · Australia · Austria - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
This study is looking into a new treatment called efgartigimod for people with Primary Sjögren's Syndrome. It aims to see how well it works and if it's safe. Participants will either receive the new medicine or a dummy treatment, and the study will last about two years.
For: Primary Sjogrens DiseaseUnited States · Argentina · Australia - RecruitingPHASE2, PHASE3
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
This study is testing a new medicine, efgartigimod PH20 SC, for children aged 2 to 17 with a muscle weakness condition called generalised Myasthenia Gravis. We want to find the best dose and make sure it's safe. Participants will get injections and be monitored.
For: Generalized Myasthenia GravisUnited States · Belgium · Canada - Active not recruitingPHASE3
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
This study looks at a new injection called efgartigimod for adults with primary immune thrombocytopenia (ITP). It aims to see how safe and effective it is. If you've been in a previous study for this treatment, you might be able to continue.
For: Primary Immune ThrombocytopeniaUnited States · Argentina · Australia - Recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
This study looks at how a treatment called efgartigimod works for people in the UK with a nerve condition called CIDP. It aims to understand patients' experiences, how they use healthcare, and if the treatment is effective in real life.
For: Chronic Inflammatory Demyelinating Polyradiculoneuropathy · CIDP · CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)United States · Germany